These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 23876164)
21. Prevalence of and risk factors for dysglycemia in patients receiving gatifloxacin and levofloxacin in an outpatient setting. LaPlante KL; Mersfelder TL; Ward KE; Quilliam BJ Pharmacotherapy; 2008 Jan; 28(1):82-9. PubMed ID: 18154478 [TBL] [Abstract][Full Text] [Related]
22. Risk of retinal tear or detachment with oral fluoroquinolone use: a cohort study. Eftekhari K; Ghodasra DH; Haynes K; Chen J; Kempen JH; VanderBeek BL Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):745-52. PubMed ID: 24757075 [TBL] [Abstract][Full Text] [Related]
23. Risk of Aortic Dissection and Aortic Aneurysm in Patients Taking Oral Fluoroquinolone. Lee CC; Lee MT; Chen YS; Lee SH; Chen YS; Chen SC; Chang SC JAMA Intern Med; 2015 Nov; 175(11):1839-47. PubMed ID: 26436523 [TBL] [Abstract][Full Text] [Related]
24. An investigation of the potential association between retinal detachment and oral fluoroquinolones: a self-controlled case series study. Chui CS; Man KK; Cheng CL; Chan EW; Lau WC; Cheng VC; Wong DS; Yang Kao YH; Wong IC J Antimicrob Chemother; 2014 Sep; 69(9):2563-7. PubMed ID: 24833754 [TBL] [Abstract][Full Text] [Related]
26. Oral fluoroquinolone use and serious arrhythmia: bi-national cohort study. Inghammar M; Svanström H; Melbye M; Pasternak B; Hviid A BMJ; 2016 Feb; 352():i843. PubMed ID: 26920666 [TBL] [Abstract][Full Text] [Related]
27. Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study. Etminan M; Forooghian F; Maberley D CMAJ; 2012 May; 184(8):E431-4. PubMed ID: 22470169 [TBL] [Abstract][Full Text] [Related]
28. Risk factors for hyperglycemia in hospitalized adults receiving gatifloxacin: a retrospective, nested case-controlled analysis. Mohr JF; Peymann PJ; Troxell E; Lodise TP; Ostrosky-Zeichner L Clin Ther; 2008 Jan; 30(1):152-7. PubMed ID: 18343251 [TBL] [Abstract][Full Text] [Related]
29. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Stevens V; Dumyati G; Fine LS; Fisher SG; van Wijngaarden E Clin Infect Dis; 2011 Jul; 53(1):42-8. PubMed ID: 21653301 [TBL] [Abstract][Full Text] [Related]
30. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Pépin J; Saheb N; Coulombe MA; Alary ME; Corriveau MP; Authier S; Leblanc M; Rivard G; Bettez M; Primeau V; Nguyen M; Jacob CE; Lanthier L Clin Infect Dis; 2005 Nov; 41(9):1254-60. PubMed ID: 16206099 [TBL] [Abstract][Full Text] [Related]
31. Detection of fluoroquinolone-induced tendon disorders using a hospital database in Japan. Hori K; Yamakawa K; Yoshida N; Ohnishi K; Kawakami J Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):886-9. PubMed ID: 22532516 [TBL] [Abstract][Full Text] [Related]
33. Safety and tolerability of commonly prescribed oral antibiotics for the treatment of respiratory tract infections. Lode H Am J Med; 2010 Apr; 123(4 Suppl):S26-38. PubMed ID: 20350633 [TBL] [Abstract][Full Text] [Related]
34. Association between oral fluoroquinolones and seizures: A self-controlled case series study. Chui CS; Chan EW; Wong AY; Root A; Douglas IJ; Wong IC Neurology; 2016 May; 86(18):1708-15. PubMed ID: 27053716 [TBL] [Abstract][Full Text] [Related]
35. The risk profile of rhegmatogenous retinal detachment before and after using a fluoroquinolone: a 12 year nationwide self-controlled case series study. Shin JY; Jeong S; Jeon HL; Byun S; Park KH; Jeong HE; Park SJ J Antimicrob Chemother; 2018 Dec; 73(12):3442-3453. PubMed ID: 30165476 [TBL] [Abstract][Full Text] [Related]
36. Analyses of fluoroquinolones and Clostridium difficile-associated diarrhoea in tuberculosis patients. Chang KC; Leung CC; Yew WW; Lam FM; Ho PL; Chau CH; Cheng VC; Yuen KY Int J Tuberc Lung Dis; 2009 Mar; 13(3):341-6. PubMed ID: 19275794 [TBL] [Abstract][Full Text] [Related]
37. Severe dysglycemia with the fluoroquinolones: a class effect? Aspinall SL; Good CB; Jiang R; McCarren M; Dong D; Cunningham FE Clin Infect Dis; 2009 Aug; 49(3):402-8. PubMed ID: 19545207 [TBL] [Abstract][Full Text] [Related]
38. Treatment failures secondary to drug interactions with divalent cations and fluoroquinolone. Suda KJ; Garey KW; Danziger LH Pharm World Sci; 2005 Apr; 27(2):81-2. PubMed ID: 15999916 [TBL] [Abstract][Full Text] [Related]
40. Fluoroquinolone use is not associated with the change in imipenem susceptibility of Pseudomonas aeruginosa in 25 hospitals. Eagye KJ; Nicolau DP Adv Ther; 2011 Apr; 28(4):326-33. PubMed ID: 21445549 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]